{"id":"leuprolide-acetate-formulation-b","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"10-20","effect":"Injection site reaction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"5-15","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Gynecomastia"},{"rate":"5-15","effect":"Bone pain (flare reaction)"}]},"_chembl":{"chemblId":"CHEMBL1200775","moleculeType":"Protein","molecularWeight":"1269.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprolide works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in profound reduction of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions. The sustained-release formulation (Formulation B) provides prolonged therapeutic effect over weeks to months.","oneSentence":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:38.449Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"},{"name":"Breast cancer (hormone-receptor positive)"}]},"trialDetails":[{"nctId":"NCT00635817","phase":"PHASE3","title":"A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-06","conditions":"Puberty, Precocious","enrollment":84},{"nctId":"NCT00626431","phase":"PHASE3","title":"A Study of Leuprolide to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":310},{"nctId":"NCT00161421","phase":"PHASE2","title":"Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone","status":"COMPLETED","sponsor":"University of Washington","startDate":"2005-03","conditions":"Contraception, Hypogonadism","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lupron","leuprorelin","gonadotropin hormone-releasing hormone (GnRH)","luteinizing hormone-releasing hormone (LHRH)"],"phase":"phase_3","status":"active","brandName":"Leuprolide acetate - Formulation B","genericName":"Leuprolide acetate - Formulation B","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Advanced prostate cancer, Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}